Login
$NEUP
$2.52 +$0.04 (1.43%) After hours

$NEUP SEC Filings

Filed On Filing
16 Nov 2026 QUARTERLY REPORT
23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders

This Amendment No. 1, dated as of October 23, 2026 (this “Amendment”), amends that certain Rights Agreement, dated as of October 27, 2025 (the “Rights Agreement”), by and between Neuphoria Therapeutics Inc., a Delaware corporation (the “...

05 Oct 2026 SCHEDULE 13G
18 Sep 2026 DEFA14A
18 Sep 2026 DEFA14A
18 Sep 2026 Proxy statement: annual meeting on November 2, 2026
18 Sep 2026 10-K
28 Jul 2026 SCHEDULE 13G/A
24 Jul 2026 CURRENT REPORT
24 Jul 2026 8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +1 more

This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of July 23, 2026, is entered into by and among Scancell Holdings plc, a public limited company incorporated under the laws of England and Wales (“Parent”), Scancell Merger Su...

26 May 2026 8-K: Other Events

On May 21, 2026, Neuphoria Therapeutics Inc. (the “Company”) received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s l...

15 May 2026 10-Q
17 Feb 2026 10-Q
06 Feb 2026 SCHEDULE 13G/A
21 Jan 2026 Form 4: Wilson David Ian, Director

Granted 8,537 Restricted Stock Units

21 Jan 2026 Form 4: Davies Peter Miles Winston, Director

Granted 8,537 Restricted Stock Units

21 Jan 2026 Form 4: Fisher Alan, Director

Granted 17,073 Restricted Stock Units

21 Jan 2026 Form 4: Ryan Jane, Director

Granted 8,537 Restricted Stock Units

08 Jan 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

THIS INDEPENDENT CONTRACTOR AGREEMENT (“Agreement”) is effective as of January 1, 2026 (the “Effective Date”) by and between Neuphoria Therapeutics, Inc., a Delaware corporation (the “Company”), and Spyridon “Spyros” Papapetropoulos (“In...

29 Dec 2025 SCHEDULE 13D/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support